A detailed history of Wells Fargo & Company transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Wells Fargo & Company holds 65,085 shares of BMRN stock, worth $4.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,085
Previous 134,166 51.49%
Holding current value
$4.31 Million
Previous $11 Million 58.59%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $4.77 Million - $6.48 Million
-69,081 Reduced 51.49%
65,085 $4.57 Million
Q2 2024

Aug 13, 2024

SELL
$74.43 - $92.22 $20.1 Million - $24.9 Million
-270,400 Reduced 66.84%
134,166 $11 Million
Q1 2024

May 10, 2024

BUY
$83.81 - $99.0 $16.3 Million - $19.3 Million
195,003 Added 93.05%
404,566 $35.3 Million
Q4 2023

Feb 09, 2024

SELL
$76.22 - $98.51 $2.99 Million - $3.87 Million
-39,267 Reduced 15.78%
209,563 $20.2 Million
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $697,914 - $775,113
8,204 Added 3.41%
248,830 $22 Million
Q2 2023

Aug 15, 2023

SELL
$86.68 - $100.3 $8.94 Million - $10.3 Million
-103,088 Reduced 29.99%
240,626 $20.9 Million
Q1 2023

May 12, 2023

SELL
$87.74 - $117.27 $562,062 - $751,231
-6,406 Reduced 1.83%
343,714 $33.4 Million
Q4 2022

Feb 13, 2023

BUY
$80.93 - $108.63 $217,297 - $291,671
2,685 Added 0.77%
350,120 $36.2 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $1.47 Million - $1.74 Million
17,932 Added 5.44%
347,435 $29.5 Million
Q2 2022

Aug 12, 2022

SELL
$71.48 - $86.85 $1.8 Million - $2.19 Million
-25,224 Reduced 7.11%
329,503 $27.3 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $4.33 Million - $5.41 Million
58,349 Added 19.69%
354,727 $27.4 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $4.49 Million - $5.73 Million
62,642 Added 26.8%
296,378 $26.2 Million
Q3 2021

Nov 15, 2021

SELL
$74.77 - $85.47 $1.81 Million - $2.07 Million
-24,227 Reduced 9.39%
233,736 $18.1 Million
Q2 2021

Aug 16, 2021

SELL
$75.51 - $84.79 $5.8 Million - $6.51 Million
-76,787 Reduced 22.94%
257,963 $21.5 Million
Q1 2021

May 13, 2021

SELL
$74.73 - $90.69 $16.1 Million - $19.5 Million
-214,799 Reduced 39.09%
334,750 $25.3 Million
Q4 2020

Feb 09, 2021

BUY
$72.61 - $90.2 $814,538 - $1.01 Million
11,218 Added 2.08%
549,549 $48.2 Million
Q3 2020

Nov 05, 2020

SELL
$71.87 - $131.03 $42.3 Million - $77.2 Million
-589,175 Reduced 52.25%
538,331 $41 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $8.63 Million - $13.5 Million
108,423 Added 10.64%
1,127,506 $139 Million
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $72.7 Million - $98.7 Million
1,019,083 New
1,019,083 $86.1 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.